+

PE20060662A1 - Procedimiento para producir derivados de amina opticamente activos - Google Patents

Procedimiento para producir derivados de amina opticamente activos

Info

Publication number
PE20060662A1
PE20060662A1 PE2005001052A PE2005001052A PE20060662A1 PE 20060662 A1 PE20060662 A1 PE 20060662A1 PE 2005001052 A PE2005001052 A PE 2005001052A PE 2005001052 A PE2005001052 A PE 2005001052A PE 20060662 A1 PE20060662 A1 PE 20060662A1
Authority
PE
Peru
Prior art keywords
procedure
furan
optically active
tetrahidro
indeno
Prior art date
Application number
PE2005001052A
Other languages
English (en)
Inventor
Shinichi Urayama
Eigo Mutou
Takashi Okada
Shigeharu Sugisaki
Atsushi Inagaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36059992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20060662A1 publication Critical patent/PE20060662A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

REFERIDA A UN PROCEDIMIENTO PARA PRODUCIR (S)-2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4b]FURAN-8-IL)ETILAMINA, CARACTERIZADO PORQUE COMPRENDE: (i) REDUCIR ASIMETRICAMENTE (E)-2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4b]FURAN-8-IL)ETILAMINA CON UN CATALIZADOR Y (ii) REDUCIR CATALITICAMENTE EL PRODUCTO DE REACCION OBTENIDO EN (i) A UNA TEMPERATURA DE ENTRE 40°C Y 100°C Y A UN PH DE ENTRE 3 Y 9 CON UN CATALIZADOR. EL CATALIZADOR EN LA ETAPA (i) ES Ru-BINAP Y EN LA ETAPA (ii) ES Pd-C. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION DE LOS CRISTALES DE (S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4b]FURAN-8-IL)ETIL]PROPIONAMIDA, CARACTERIZADO POR: (a) LA PROPIONILACION DE (S)-2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4b]FURAN-8-IL)ETILAMINA OBTENIDA EN EL PROCEDIMIENTO ANTERIOR Y (b) CRISTALIZAR AGREGANDO EL SOLVENTE ACUOSO A LA SOLUCION DE REACCION OBTENIDA EN LA ETAPA (a). DICHO PROCEDIMIENTO ES UTIL PARA PRODUCIR DERIVADOS DE AMINA OPTICAMENTE ACTIVOS CON ELEVADA PUREZA, EN DONDE SE SUPRIME LA FORMACION DE PRODUCTOS COLATERALES
PE2005001052A 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos PE20060662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004265307 2004-09-13

Publications (1)

Publication Number Publication Date
PE20060662A1 true PE20060662A1 (es) 2006-08-22

Family

ID=36059992

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2008001369A PE20081390A1 (es) 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos
PE2012001990A PE20130154A1 (es) 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos
PE2005001052A PE20060662A1 (es) 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2008001369A PE20081390A1 (es) 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos
PE2012001990A PE20130154A1 (es) 2004-09-13 2005-09-09 Procedimiento para producir derivados de amina opticamente activos

Country Status (32)

Country Link
US (4) US8097737B2 (es)
EP (2) EP2537842A1 (es)
JP (2) JP5127228B2 (es)
KR (1) KR101298335B1 (es)
CN (2) CN102516211A (es)
AR (1) AR050737A1 (es)
AU (1) AU2005283521B2 (es)
BR (1) BRPI0515170A (es)
CA (2) CA2764314C (es)
CR (2) CR8975A (es)
EC (1) ECSP077317A (es)
ES (1) ES2485890T3 (es)
GE (1) GEP20094725B (es)
GT (2) GT200500257A (es)
HN (1) HN2005000548A (es)
IL (2) IL181462A (es)
MA (1) MA28855B1 (es)
MX (1) MX2007002822A (es)
MY (2) MY147822A (es)
NO (1) NO20071866L (es)
NZ (1) NZ553562A (es)
PA (1) PA8645701A1 (es)
PE (3) PE20081390A1 (es)
PH (1) PH12012501172A1 (es)
RU (1) RU2385318C2 (es)
SA (1) SA05260347A (es)
SG (1) SG151330A1 (es)
TW (1) TWI400220B (es)
UA (1) UA95598C2 (es)
UY (1) UY29118A1 (es)
WO (1) WO2006030739A1 (es)
ZA (1) ZA200701724B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123067A1 (ja) * 2007-03-19 2008-10-16 Takeda Pharmaceutical Company Limited アリルアミン不斉水素化法
WO2008150953A1 (en) * 2007-05-30 2008-12-11 Dr. Reddy's Laboratories Ltd. Process of making ramelteon and related substances
WO2008151170A2 (en) * 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
CN101531647B (zh) * 2008-03-13 2012-10-31 常州亚邦制药有限公司 (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法
CN102099348A (zh) * 2008-07-14 2011-06-15 力奇制药公司 作为用于制备拉米替隆的中间体的6，7-二氢-1h-吲哚并[5，4-b]呋喃-8(2h)-酮的合成方法
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2010092107A1 (en) 2009-02-12 2010-08-19 Lek Pharmaceuticals D.D. Synthesis of (s)-n-[2-(1,6,7,8-tetrahydro-2h-indeno-[5,4-b]furan-8-yl)ethyl]propionamide
CN101824012B (zh) * 2009-03-02 2011-12-07 四川大学 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途
CA2754802A1 (en) 2009-03-10 2010-09-16 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
WO2011027323A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of ramelteon
WO2011027319A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of an intermediate for ramelteon
CN101648931B (zh) * 2009-09-21 2012-05-09 四川大学 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法
CN101665477B (zh) * 2009-09-21 2012-05-09 四川大学 (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途
CN102648192B (zh) 2009-09-29 2015-08-26 广州南沙龙沙有限公司 1,2,6,7-四氢-8h-茚并[5,4-b] 呋喃-8-酮的制备方法
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN103664849B (zh) * 2012-08-31 2017-03-29 上海阳帆医药科技有限公司 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
CN103396387A (zh) * 2013-08-07 2013-11-20 安徽联创药物化学有限公司 雷美替胺中间体的制备方法
CN105277628B (zh) * 2014-07-07 2017-05-31 南京长澳医药科技有限公司 通过高效液相色谱法分离测定雷美替胺及其杂质的方法
CN104402848B (zh) * 2014-09-22 2017-02-08 珠海联邦制药股份有限公司 雷美替胺中的杂质化合物的制备方法及制备的标准品
CN105622557B (zh) * 2014-11-05 2018-12-04 上海医药工业研究院 雷美替胺中间体及其制备方法
KR102359229B1 (ko) 2020-04-16 2022-02-07 제이투에이치바이오텍 (주) 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물
CN115477628A (zh) * 2022-10-17 2022-12-16 江苏海悦康医药科技有限公司 一种雷美替胺二聚体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
PT812835E (pt) 1995-03-02 2001-08-30 Sankyo Co Derivados opticamente activos de tiazolidinona
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
CA2241666C (en) * 1996-03-08 2007-11-06 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP1199304A1 (en) * 1997-03-05 2002-04-24 Takeda Chemical Industries, Ltd. Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
JP4242940B2 (ja) 1997-02-13 2009-03-25 高砂香料工業株式会社 光学活性アミン誘導体の製造法
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
ATE247967T1 (de) * 1998-06-09 2003-09-15 Takeda Chemical Industries Ltd Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
JP3633895B2 (ja) 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
DE60142305D1 (de) * 2000-11-17 2010-07-15 Takeda Pharmaceutical Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Also Published As

Publication number Publication date
CR20110698A (es) 2012-03-08
CN101056867B (zh) 2011-12-07
KR101298335B1 (ko) 2013-08-20
NZ553562A (en) 2010-08-27
PE20081390A1 (es) 2008-10-24
RU2007113811A (ru) 2008-10-20
SA05260347A (ar) 2005-12-03
RU2385318C2 (ru) 2010-03-27
UA95598C2 (ru) 2011-08-25
CA2579121C (en) 2013-07-30
CN102516211A (zh) 2012-06-27
KR20070054200A (ko) 2007-05-28
CA2764314A1 (en) 2006-03-23
NO20071866L (no) 2007-05-29
US20090036521A1 (en) 2009-02-05
JPWO2006030739A1 (ja) 2008-05-15
US20140066499A1 (en) 2014-03-06
PE20130154A1 (es) 2013-02-27
US20120088826A1 (en) 2012-04-12
SG151330A1 (en) 2009-04-30
AU2005283521B2 (en) 2011-10-13
CA2579121A1 (en) 2006-03-23
PA8645701A1 (es) 2006-09-22
EP1792899B1 (en) 2014-07-09
EP1792899A1 (en) 2007-06-06
PH12012501172A1 (en) 2014-04-28
MY147822A (en) 2013-01-31
US20130079397A1 (en) 2013-03-28
US8097737B2 (en) 2012-01-17
JP5127228B2 (ja) 2013-01-23
EP2537842A1 (en) 2012-12-26
MY158073A (en) 2016-08-30
JP2012116848A (ja) 2012-06-21
IL181462A (en) 2011-12-29
US8609871B2 (en) 2013-12-17
ZA200701724B (en) 2008-08-27
GT200500257AA (es) 2008-07-28
GEP20094725B (en) 2009-07-10
IL207510A (en) 2013-02-28
MX2007002822A (es) 2007-04-23
ES2485890T3 (es) 2014-08-14
TWI400220B (zh) 2013-07-01
UY29118A1 (es) 2006-06-30
CR8975A (es) 2007-08-28
JP5615304B2 (ja) 2014-10-29
MA28855B1 (fr) 2007-09-03
WO2006030739A1 (ja) 2006-03-23
TW200613239A (en) 2006-05-01
ECSP077317A (es) 2007-04-26
HN2005000548A (es) 2007-04-20
CN101056867A (zh) 2007-10-17
IL181462A0 (en) 2007-07-04
AU2005283521A1 (en) 2006-03-23
GT200500257A (es) 2006-04-17
CA2764314C (en) 2014-06-17
EP1792899A4 (en) 2009-12-16
BRPI0515170A (pt) 2008-07-08
AR050737A1 (es) 2006-11-15

Similar Documents

Publication Publication Date Title
PE20060662A1 (es) Procedimiento para producir derivados de amina opticamente activos
AR068527A2 (es) Un procedimiento para preparar monohidrato de bromuro de tiotropio cristalino
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
AR029857A1 (es) Derivados de acidos sulfonil-amino-metil-benzoicos sustituidos y procedimiento para su preparacion
ES2173499T3 (es) Sales de adicion de acidos de compuesto de piperidina opticamente activo y procedimiento para su preparacion.
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
EA201070719A1 (ru) Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты
CO5650226A2 (es) Forma cristalina del agonista del receptor adrenergico beta
AR059763A2 (es) Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir
AR039857A1 (es) Preparaciones de una sulfinilacetamida
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
PE20080365A1 (es) Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
RU2008103699A (ru) Кристаллические формы динатриевой соли n-(-5-хлорсалицило-)-8-аминокаприловой кислоты
AR043993A1 (es) Procedimiento para la sintesis del acido (2s)-indolina-2-carboxilico y aplicacion en la sistesis del perindopril
PE20020845A1 (es) Derivados de o -amino-n-hidroxi-acetamida
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
PT1272495E (pt) Processo para a preparacao de cefoperazona de sodio altamente cristalina
PE20011260A1 (es) Derivados de sulfonamida
AR060622A1 (es) Proceso para la preparcion del ester 2-[ 4-(4- fluoro-2 - metil-1h -indol-5- iloxi)-5-metil pirrolo [2,1-f] [ 1,2,4] triazin -6-iloxi] -1- metiletilico del acido [(1r),2s ] -2- aminopropinoico
MXPA06000945A (es) Preparacion de sales metalicas de acidos grasos de cadena mediana.
AR051933A1 (es) Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida
ES2049700T1 (es) Sal cristalina de la s-carboximetilcisteina lisina monohidratada y procedimiento para su fabricacion.
PE20091566A1 (es) (R)-N*6*-ETIL-6,7-DIHIDRO-5H-INDENO[5,6-d]TIAZOL-2,6-DIAMINA Y SUS SALES Y UN PROCEDIMIENTO PARA SU PREPARACION
ES2195752B1 (es) Procedimiento para la preparacion de polimorfos cristalinos de la sal sodica del fosinopril.
AR058168A1 (es) Sintesis del alendronato de sodio trihidratado

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载